We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+19.02%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$2.7B
AUM Growth
-$133M
(-4.7%)
Cap. Flow
-$358M
Cap. Flow
% of AUM
-13.27%
Top 10 Holdings %
Top 10 Hldgs %
54.24%
Holding
107
New
20
Increased
12
Reduced
35
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$157M |
| 2 |
OMDA
Omada Health Inc
OMDA
|
+$42M |
| 3 |
Roivant Sciences
ROIV
|
+$36.1M |
| 4 |
CAI
Caris Life Sciences
CAI
|
+$29.6M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$17.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$104M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$90.7M |
| 3 |
SLNO
Soleno Therapeutics
SLNO
|
+$80.5M |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$78.2M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$42.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Ocular Therapeutix
OCUL
$1.96B
| – | – |
-915,775
| Closed | -$6.71M |
|
102
Vaxcyte
PCVX
$8.12B
| – | – |
-706,567
| Closed | -$26.7M |
|
103
Rocket Pharmaceuticals
RCKT
$376M
| – | – |
-140,726
| Closed | -$939K |
|
104
Traws Pharma
TRAW
$10.2M
| – | – |
-421,781
| Closed | -$970K |
|
|
OKUR
105
OnKure Therapeutics
OKUR
$170M
| – | – |
-1,004,439
| Closed | -$4.32M |
|
|
KMTS
106
Kestra Medical Technologies
KMTS
$1.43B
| – | – |
-200,000
| Closed | -$4.98M |
|
|
ITCI
107
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-786,358
| Closed | -$104M |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q2 2025 Portfolio in Review
As of Q2 2025, Perceptive Advisors held 107 positions worth $2.7B, down 4.7% from $2.83B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Perceptive Advisors withdrew a net $358M in Q2 2025, closing 22 positions and reducing 35 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $104M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.
Against the trend, Perceptive Advisors opened a new position in Ascendis Pharma A/S worth $166M.
- Perceptive Advisors's largest Q2 2025 buy was Ascendis Pharma A/S: 963,886 shares worth $166M.
- Perceptive Advisors added most to Neurocrine Biosciences in Q2 2025, an estimated $17.8M increase.
- Perceptive Advisors's biggest Q2 2025 reduction was Amicus Therapeutics, cutting an estimated $90.7M.
- Perceptive Advisors fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $104M.
- Perceptive Advisors's ten largest holdings make up 54% of its $2.7B portfolio in Q2 2025.
- Perceptive Advisors opened 20 new positions and closed 22 in Q2 2025.
- Perceptive Advisors's portfolio value fell 4.7% quarter-over-quarter to $2.7B.
Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.